Trials / Completed
CompletedNCT01954251
Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 829 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess immunogenicity, reactogenicity and safety of GSK Biologicals' HZ/su vaccine when its first dose is co-administered with the FLU-D-QIV vaccine in adults aged 50 years or older compared to administration of vaccines separately.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Herpes Zoster vaccine GSK 1437173A | 2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm. |
| BIOLOGICAL | GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A | 2 doses administered intramuscularly (IM) in the deltoid region of the dominant arm. |
Timeline
- Start date
- 2013-10-03
- Primary completion
- 2014-06-02
- Completion
- 2015-03-20
- First posted
- 2013-10-01
- Last updated
- 2018-05-02
- Results posted
- 2016-02-10
Locations
20 sites across 3 countries: United States, Canada, Germany
Source: ClinicalTrials.gov record NCT01954251. Inclusion in this directory is not an endorsement.